List of bibliographic references
Number of relevant bibliographic references: 8.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Eculizumab |
| 4 | Nocturnal paroxystic anemia |
| 3 | Complement |
| 3 | Female |
| 3 | Hematology |
| 3 | Human |
| 3 | Humans |
| 3 | Inhibitor |
| 3 | Male |
| 2 | Dose-Response Relationship, Drug |
| 2 | Hemolysis |
| 2 | Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy) |
| 2 | Middle Aged |
| 1 | Adult |
| 1 | Aged |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 1 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 1 | Antibodies, Neutralizing (blood) |
| 1 | Antineoplastic Agents (administration & dosage) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Bendamustine Hydrochloride (administration & dosage) |
| 1 | Cancerology |
| 1 | Complement C5 (antagonists & inhibitors) |
| 1 | Complement Inactivating Agents (administration & dosage) |
| 1 | Complement Inactivating Agents (adverse effects) |
| 1 | Complement Inactivating Agents (therapeutic use) |
| 1 | Disease-Free Survival |
| 1 | Double-Blind Method |
| 1 | Drug Resistance, Neoplasm (drug effects) |
| 1 | Embolism |
| 1 | Follow-Up Studies |
| 1 | Hemoglobin |
| 1 | Hemoglobinuria, Paroxysmal (blood) |
| 1 | Hemoglobinuria, Paroxysmal (drug therapy) |
| 1 | Hemoglobinuria, Paroxysmal (immunology) |
| 1 | Hemolysis (drug effects) |
| 1 | Hemolysis (immunology) |
| 1 | Immunomodulator |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (genetics) |
| 1 | Leukemia, Lymphocytic, Chronic, B-Cell (pathology) |
| 1 | Long term |
| 1 | Medicine |
| 1 | Mutation |
| 1 | Neoplasm Recurrence, Local (drug therapy) |
| 1 | Neoplasm Recurrence, Local (pathology) |
| 1 | Neoplasm Staging |
| 1 | Patient Compliance |
| 1 | Prognosis |
| 1 | Protein Kinase Inhibitors (administration & dosage) |
| 1 | Protein Kinase Inhibitors (therapeutic use) |
| 1 | Protein-Tyrosine Kinases (antagonists & inhibitors) |
| 1 | Purines (administration & dosage) |
| 1 | Pyrazoles (administration & dosage) |
| 1 | Pyrazoles (therapeutic use) |
| 1 | Pyrimidines (administration & dosage) |
| 1 | Pyrimidines (therapeutic use) |
| 1 | Quinazolinones (administration & dosage) |
| 1 | Rituximab (administration & dosage) |
| 1 | Salvage Therapy |
| 1 | Survival Rate |
| 1 | Thromboembolism |
| 1 | Thrombosis |
| 1 | Time Factors |
| 1 | Transfusion |
| 1 | Treatment |
| 1 | Treatment efficiency |
| 1 | Tumor Suppressor Protein p53 (genetics) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Peter Hillmen"
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i \
-Sk "Peter Hillmen" \
| HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= UK
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Peter Hillmen
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
